Actavia Life Sciences (Actavia Life Sciences) Short-Term Debt : $0.23 Mil (As of Dec. 2023)

View and export this data going back to 2014. Start your Free Trial

What is Actavia Life Sciences Short-Term Debt?

Actavia Life Sciences's Short-Term Debt for the quarter that ended in Dec. 2023 was $0.23 Mil.

Actavia Life Sciences's quarterly Short-Term Debt declined from Jun. 2023 ($0.22 Mil) to Sep. 2023 ($0.21 Mil) but then increased from Sep. 2023 ($0.21 Mil) to Dec. 2023 ($0.23 Mil).

Actavia Life Sciences's annual Short-Term Debt declined from Sep. 2021 ($0.68 Mil) to Sep. 2022 ($0.13 Mil) but then increased from Sep. 2022 ($0.13 Mil) to Sep. 2023 ($0.21 Mil).

Actavia Life Sciences Short-Term Debt Historical Data

The historical data trend for Actavia Life Sciences's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Actavia Life Sciences Short-Term Debt Chart

Actavia Life Sciences Annual Data

Trend

Jun14

Jun15

Jun16

Mar17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Short-Term Debt

Get a 7-Day Free Trial

0.27

0.52

0.68

0.13

0.21

Actavia Life Sciences Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Short-Term Debt	Get a 7-Day Free Trial															0.13	0.22	0.22	0.21	0.23

Actavia Life Sciences Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Actavia Life Sciences Short-Term Debt Related Terms

Thank you for viewing the detailed overview of Actavia Life Sciences's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Actavia Life Sciences (Actavia Life Sciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Actavia Life Sciences Inc (OTCPK:RASP) » Definitions » Short-Term Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

420 Lexington Avenue, Suite 2525, New York, NY, USA, 10170

Website

https://www.rasna.com

Rasna Therapeutics Inc is a clinical-stage biotechnology company focused on targeted drugs to treat diseases in oncology and immunology, mainly focusing on the treatment of leukemia. Its primary indication is Acute Myeloid Leukemia (AML), which may be fatal within weeks to months, has about a 5-year survival rate of only about 25% and very poor prospects for the long-term survival of patients.

Actavia Life Sciences (Actavia Life Sciences) Headlines

No Headlines